Anavex Life Sciences Regains Nasdaq Compliance After Filing Delinquent 10‑Qs

What Happened
Anavex Life Sciences Corp. announced on September 2, 2026 that Nasdaq has confirmed the company has regained compliance with Nasdaq Listing Rule 5250(c)(1). The company had received a delinquency notice on May 20, 2026 for failing to timely file its Quarterly Report on Form 10‑Q for the quarter ended March 31, 2026. Anavex submitted a compliance plan to Nasdaq on July 20, 2026 and on August 28, 2026 filed its Form 10‑Q for the quarter ended March 31, 2026 and its Form 10‑Q for the quarter ended June 30, 2026. A press release dated September 2, 2026 confirming Nasdaq’s notice is attached to the 8‑K.

Key Details

• Delinquency notice received: May 20, 2026 — noncompliance with Nasdaq Listing Rule 5250(c)(1) for late Form 10‑Q.
• Compliance plan submitted: July 20, 2026 — Anavex’s plan to regain compliance.
• Filings made: August 28, 2026 — filed Form 10‑Q for periods ended March 31, 2026 and June 30, 2026.
• Regained compliance confirmed: September 2, 2026 — Nasdaq notified the company it is back in compliance; press release attached as Exhibit 99.1.

Why It Matters
Regaining compliance removes the immediate risk of Nasdaq delisting tied to late periodic reports and restores the company’s standing as a reporting issuer, which is important for share trading and investor confidence. For investors, the important facts are that Anavex’s quarterly reports (10‑Qs) are now filed and current; the 8‑K does not disclose any related financial restatements or changes to executive leadership. Investors should review the newly filed 10‑Qs for updated quarterly results, revenue/expense details, and any disclosures that may affect valuation or near‑term prospects.